Effect of rosuvastatin on serum hsCRP, IL-18 levels in patients with acute myocardial infarction / 中国基层医药

ABSTRACT

Objective To observe the effect of rosuvastatin on serum hs-CRP,IL-18 levels in patients with acute myocardial infarction.Methods By randomized,double-blind,controlled study,102 patients with acute myocardial infarction were randomly divided into the treatment group(rosuvastatin 10mg/d,continuous medication 14d) and the control group(not used rosuvastatin,other treatment and care were same with the treatment group).Before treatment,24h after treatment,after 2 months of follow-up,the serum hs-CRP and IL-18 levels were detected and compared.Results After treatment,the serum hsCRP level increased and then decreased,24h after treatment,the serum hsCRP level of the treatment group increased to (15.54 ±2.51) mg/L,which was significantly lower than the control group (19.26 ±.2.92) mg/L (t =4.65,all P ＜ 0.05).2 months after treatment,the serum hs-CRP levels of the two groups were decreased to (3.21 ± 1.39) mg/L and (7.67 ± 2.07) mg/L,the difference was statistically significant (t =5.54,4.63,all P ＜ 0.05).After treatment,the serum IL-18 level decreased,24h after treatment,the serum IL-18 level ofthe treatment group decreased to (29.13 ±6.34)pg/L,which was significandy lower than the control group (33.01 ± 7.34) pg/L(t =3.59,P ＜ 0.05).2 months after treatment,serum IL-18 levels of the two groups were decreased to (27.52 ± 5.33) pg/L and (32.01 ± 6.24) pg/L,the difference was statistically significant (t =3.87,3.28,P ＜0.05).Conclusion Rosuvastatin can significantly reduce the serum hsCRP and IL-18 levels in patients with acute coronary syndrome,it has better anti-inflammatory effect and can be used as a new therapeutic target for acute myocardial infarction.